Vir Biotechnology, Inc. Common Stock
VIR
VIR: Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
moreShow VIR Financials
Recent trades of VIR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VIR's directors and management
Government lobbying spending instances
-
$160,000 Jul 20, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Apr 20, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$150,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$170,000 Apr 20, 2022 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$120,000 Jan 20, 2022 Issue: None
-
$170,000 Oct 20, 2021 Issue: None
-
$30,000 Jul 19, 2021 Issue: Health Issues
-
$90,000 Jul 18, 2021 Issue: Health Issues Government Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues
-
$90,000 Apr 20, 2021 Issue: Health Issues Government Issues
-
$90,000 Jan 20, 2021 Issue: Budget/Appropriations Government Issues Health Issues
-
$30,000 Jan 19, 2021 Issue: Health Issues
-
$90,000 Oct 20, 2020 Issue: Health Issues Budget/Appropriations Government Issues
-
$90,000 Jul 19, 2020 Issue: Government Issues Health Issues
New patents grants
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Apr. 18, 2023
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Jan. 17, 2023
-
Patent Title: Antibodies against sars-cov-2 and methods of using the same Oct. 25, 2022
-
Patent Title: Antibodies against sars-cov-2 and methods of using the same Nov. 09, 2021
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Jan. 19, 2021
Federal grants, loans, and purchases
Followers on VIR's company Twitter account
Number of mentions of VIR in WallStreetBets Daily Discussion
Recent insights relating to VIR
Recent picks made for VIR stock on CNBC
ETFs with the largest estimated holdings in VIR
Flights by private jets registered to VIR